Evidence map›Paper›PMID 42423792›Full record

ArticleJournal of medical ultrasonics (2001)2026

Superior accuracy of a novel multidimensional index integrating static and dynamic liver stiffness for hepatocellular carcinoma risk prediction in chronic hepatitis B.

Yusuke Sano, Naoto Kawabe, Hiroko Sugiyama, Yutaka Sasaki, Keisuke Osakabe, Eizaburo Ohno, Teiji Kuzuya, Senju Hashimoto, Yoshiki Hirooka, Naohiro Ichino

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of medical ultrasonics (2001), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yusuke SanoDepartment of Clinical Laboratory, Fujita Health University Hospital, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, 470-1192, Japan.ORCID http://orcid.org/0009-0004-7833-0576
Naoto KawabeDepartment of Gastroenterology and Hepatology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, 3-35 Michishita-cho, Nakamura-ku, Nagoya, 453-0046, Japan.
Hiroko SugiyamaDepartment of Clinical Laboratory, Fujita Health University Hospital, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, 470-1192, Japan.
Yutaka SasakiDepartment of Clinical Laboratory, Fujita Health University Hospital, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, 470-1192, Japan.
Keisuke OsakabeDepartment of Clinical Laboratory Sciences, Fujita Health University Graduate School of Medical Sciences, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, 470-1192, Japan.
Eizaburo OhnoDepartment of Gastroenterology and Hepatology, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, 470-1192, Japan.
Teiji KuzuyaDepartment of Gastroenterology and Hepatology, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, 470-1192, Japan.
Senju HashimotoDepartment of Gastroenterology and Hepatology, Fujita Health University Bantane Hospital, 3-6-10 Otobashi, Nakagawa-ku, Nagoya, 454-8509, Japan.
Yoshiki HirookaDepartment of Gastroenterology and Hepatology, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, 470-1192, Japan.
Naohiro IchinoDepartment of Clinical Laboratory, Fujita Health University Hospital, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, 470-1192, Japan. ichino@fujita-hu.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHepatitis B virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC). Although nucleoside/nucleotide analogue (NA) therapy significantly reduces this risk, a subset of patients still develop HCC. This study aimed to identify high-risk groups by evaluating the comprehensive utility of multidimensional factor combinations.

methodsWe analyzed 565 patients with chronic HBV infection who underwent liver stiffness (LS) measurement between 2009 and 2024. Independent risk factors for HCC were identified using multivariate logistic regression. In 84 patients who underwent testing before and after NA therapy, the annual rate of change in parameters was evaluated to assess dynamic risk prediction.

resultsMultivariate analysis identified male sex, LS, total bilirubin, gamma-glutamyl transpeptidase, and fibrosis-4 index as independent predictors, with LS being the most significant (cut-off value: 1.54 m/s; area under the curve: 0.811). Diagnostic accuracy (69.4%) was increased to 79.1% by applying a platelet count (PLT) cut-off value of 18.1 × 10

conclusionIntegrating cross-sectional LS and PLT measurements with the longitudinal rate of %LS significantly enhances HCC risk stratification. This approach facilitates personalized surveillance and optimized management for patients with chronic hepatitis B.

Indexed as

Hepatitis B virusHepatocellular carcinomaLiver stiffnessNA therapyRisk assessment

Identifiers

PMID42423792

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.